Citi Pharma Limited (PSX:CPHL)
Pakistan
· Delayed Price · Currency is PKR 77.93
-1.25 (-1.58%)
At close: Mar 6, 2026
Citi Pharma Income Statement
Financials in millions PKR. Fiscal year is July - June.
Millions PKR. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | 2020 - 2016 |
| Revenue | 14,097 | 13,154 | 12,409 | 12,397 | 9,780 | 5,795 | Upgrade
|
| Revenue Growth (YoY) | 6.86% | 6.00% | 0.10% | 26.76% | 68.75% | 64.29% | Upgrade
|
| Cost of Revenue | 11,571 | 11,136 | 10,823 | 10,890 | 8,417 | 5,024 | Upgrade
|
| Gross Profit | 2,526 | 2,018 | 1,586 | 1,507 | 1,363 | 771.9 | Upgrade
|
| Selling, General & Admin | 454.62 | 413.36 | 380.55 | 339.64 | 369.6 | 200.93 | Upgrade
|
| Operating Expenses | 454.62 | 413.36 | 380.55 | 339.64 | 369.6 | 200.93 | Upgrade
|
| Operating Income | 2,072 | 1,604 | 1,206 | 1,167 | 993.48 | 570.97 | Upgrade
|
| Interest Expense | -443.06 | -317.65 | -295.43 | -133.84 | -57.76 | -35.74 | Upgrade
|
| Interest & Investment Income | - | 1.92 | 23.77 | 13.54 | 20.95 | - | Upgrade
|
| Currency Exchange Gain (Loss) | -8.34 | -6.05 | 65.52 | -245.68 | -6.85 | -0.64 | Upgrade
|
| Other Non Operating Income (Expenses) | 48.07 | 69.34 | 256.3 | 175.03 | 110.75 | -34.84 | Upgrade
|
| EBT Excluding Unusual Items | 1,669 | 1,352 | 1,256 | 976.52 | 1,061 | 499.75 | Upgrade
|
| Gain (Loss) on Sale of Investments | -22.52 | 2.7 | 25.4 | -37.42 | - | - | Upgrade
|
| Other Unusual Items | - | - | - | 18.16 | - | - | Upgrade
|
| Pretax Income | 1,646 | 1,355 | 1,281 | 957.25 | 1,061 | 499.75 | Upgrade
|
| Income Tax Expense | 604.42 | 462.47 | 447.74 | 299.27 | 406.88 | 147.98 | Upgrade
|
| Net Income | 1,042 | 892.04 | 833.46 | 657.98 | 653.69 | 351.77 | Upgrade
|
| Net Income to Common | 1,042 | 892.04 | 833.46 | 657.98 | 653.69 | 351.77 | Upgrade
|
| Net Income Growth | 26.73% | 7.03% | 26.67% | 0.66% | 85.83% | 145.28% | Upgrade
|
| Shares Outstanding (Basic) | 229 | 228 | 228 | 228 | 227 | 106 | Upgrade
|
| Shares Outstanding (Diluted) | 229 | 228 | 228 | 228 | 227 | 186 | Upgrade
|
| Shares Change (YoY) | 0.13% | - | - | 0.70% | 21.65% | 88.38% | Upgrade
|
| EPS (Basic) | 4.55 | 3.90 | 3.65 | 2.88 | 2.88 | 3.31 | Upgrade
|
| EPS (Diluted) | 4.55 | 3.90 | 3.65 | 2.88 | 2.88 | 1.88 | Upgrade
|
| EPS Growth | 26.45% | 6.90% | 26.67% | - | 53.04% | 29.90% | Upgrade
|
| Free Cash Flow | -1,027 | -470.77 | 769.4 | -1,283 | -923.43 | -52.3 | Upgrade
|
| Free Cash Flow Per Share | -4.49 | -2.06 | 3.37 | -5.62 | -4.07 | -0.28 | Upgrade
|
| Dividend Per Share | 3.500 | 3.500 | 3.250 | 2.500 | - | 1.364 | Upgrade
|
| Dividend Growth | 7.69% | 7.69% | 30.00% | - | - | - | Upgrade
|
| Gross Margin | 17.92% | 15.34% | 12.78% | 12.16% | 13.94% | 13.32% | Upgrade
|
| Operating Margin | 14.70% | 12.20% | 9.72% | 9.42% | 10.16% | 9.85% | Upgrade
|
| Profit Margin | 7.39% | 6.78% | 6.72% | 5.31% | 6.68% | 6.07% | Upgrade
|
| Free Cash Flow Margin | -7.28% | -3.58% | 6.20% | -10.35% | -9.44% | -0.90% | Upgrade
|
| EBITDA | 2,256 | 1,767 | 1,341 | 1,258 | 1,066 | 631.68 | Upgrade
|
| EBITDA Margin | 16.00% | 13.43% | 10.81% | 10.15% | 10.90% | 10.90% | Upgrade
|
| D&A For EBITDA | 183.97 | 162.75 | 135.67 | 90.59 | 72.84 | 60.71 | Upgrade
|
| EBIT | 2,072 | 1,604 | 1,206 | 1,167 | 993.48 | 570.97 | Upgrade
|
| EBIT Margin | 14.70% | 12.20% | 9.72% | 9.42% | 10.16% | 9.85% | Upgrade
|
| Effective Tax Rate | 36.72% | 34.14% | 34.95% | 31.26% | 38.36% | 29.61% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.